Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Dec 16, 2024
Merus had a standout start this month. Shortly after landing a long-anticipated commercialization partner for its zenocutuzumab, the drug has achieved FDA approval, becoming the first therapy to target cancers with a neuregulin 1 (NRG1) gene fusion. The FDA granted accelerated approval to the drug, now marketed ...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper